“Looking Ahead: Palatin’s Exciting Corporate Milestones for 2025”
Palatin Technologies, Inc. Update on Anticipated Milestones in 2025 Obesity Programs Overview Palatin Technologies, Inc. has announced Phase 2 clinical studies for the BMT-801 with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide, with topline results expected in the first quarter of 2025. These studies will focus on general obesity, weight loss management, and rare…